Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
07/2004
07/15/2004US20040137048 Thermolabile liposome with controlled release temperature
07/15/2004US20040137043 microcrystalline cellulose and carrageenan and a strengthening polymer, and/or a plasticizer; does not retard the release of active ingredients when placed or ingested into an aqueous medium; dosage forms; coated candy, foods, agricultural chemical
07/15/2004US20040137041 Water-soluble natural film and its preparing method
07/15/2004US20040137034 Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
07/15/2004US20040137027 dissolving a water-soluble partially hydrolyzed polyvinyl alcohol in water to form a solution, adding flavors and fragrances and then a solubilizing additive to prevent the evaporation and dissolution of flavores from the solution, coating, drying
07/15/2004US20040137026 a cosmetically acceptable, solid electret material (with a particle size of 0.05 to 100 mu m), when brought in the electrete state has an induced permanent dipole moment and a permanent electric field with a field strength of 500 to 107 Vm-1
07/15/2004US20040137006 an anti-allergic agent, comprising a molecule having at least a first segment competent for importation of the molecule into mast cells, and a second segment for having an anti-allergic effect within the mast cells
07/15/2004US20040136997 Identification and development of specific monoclonal antibodies to squamous cell carcinoma
07/15/2004US20040136993 inducing an immunogenic response against alpha-SN
07/15/2004US20040136982 Novel monoclonal antibody
07/15/2004US20040136970 negatively charged carrier, such as hyaluronic acid, are administered to a synovial joint, the stimulatory effects of the FGF18 are enhanced
07/15/2004US20040136962 Ordered molecular presetation of antigens, method of preparation and use
07/15/2004US20040136955 Modified asialo-interferons and uses thereof
07/15/2004US20040136952 with water-soluble polymers, e.g., poly(ethylene glycol); coupling with amino-terminal amino acid located remotely from one or more receptor-binding domains of said cytokine, chemokine, growth factor or polypeptide hormone, or antagonist thereof
07/15/2004US20040136947 Polymeric prodrugs of vancomycin
07/15/2004US20040136925 mixture of hyaluronic acids of various molecular weight, properly added with suitable diluents, which demonstrated to possess an interesting antiflogistic, antioxidant and tissue repair activity
07/15/2004US20040136923 Edible film for relief of cough or symptoms associated with pharyngitis
07/15/2004US20040136922 film delivers at least one oral care agent, such as antimicrobial agents and salivary stimulants
07/15/2004US20040136920 aerosol formulation which comprises particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant
07/15/2004US20040136908 Anti-cd19 immunotoxins
07/15/2004US20040136907 Compounds with binding affinity for both alpha v beta 3 and somatostatin receptors; arginine, glycine, aspartic acid; improved overall affinity for tumors
07/15/2004US20040136904 Dry powder compositions comprising labelled particles for inhalation
07/15/2004US20040135015 Liquid formations for electrohydrodymanic spraying containing polymer and suspended particles
07/15/2004DE20320103U1 Composition for topical treatment of skin, useful for treating e.g. eczema and pruritus, comprises a fatty alcohol and three specific plant extracts
07/15/2004DE10320604A1 Partikel umfassend ein Biopolymer, das unter Einwirkung von elektromagnetischen Wellen, ausgestrahlt durch Sonneneinstrahlung, abbaubar ist Particles comprising a biopolymer that is under the influence of electromagnetic waves emitted by the sun, degradable
07/15/2004DE10260537A1 Peptide mit hohem Cysteingehalt Peptides with high cysteine
07/15/2004DE10255132A1 Composition containing peptide that includes amino acid analog, useful for treating e.g. cancer, where the peptide binds to and enters only specific target cells
07/15/2004CA2774928A1 Binding agents which inhibit myostatin
07/15/2004CA2512199A1 Compositions of benzoquinolizine carboxylic acid antibiotic drug
07/15/2004CA2510318A1 Improved nail drug delivery
07/15/2004CA2510196A1 Intracutaneous injection
07/14/2004EP1437380A1 Polymeric hydrogel
07/14/2004EP1437143A1 Injections for eye tissue containing drug bound to polyethylene glycol
07/14/2004EP1437140A1 Oral pharmaceutical formulation containing active carbon and use of the same
07/14/2004EP1437136A1 Compositions comprising cannabinoids
07/14/2004EP1437130A1 Percutaneous absorption preparations
07/14/2004EP1437127A1 Suspension comprising oxcarbazepine
07/14/2004EP1437126A1 Compositions used to alleviate xerostomia and to treat disorders associated with same
07/14/2004EP1437121A1 Anti-dandruff composition for hair and scalp
07/14/2004EP1436429A2 Targeted nucleic acid constructs and uses related thereto
07/14/2004EP1436334A1 Polymers with structure-defined functions
07/14/2004EP1436322A2 Cyclosporine analogue mixtures and their use as immunomodulating agents
07/14/2004EP1436316A2 Subcellular targeting of therapeutic proteins
07/14/2004EP1436314A2 RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIN D1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
07/14/2004EP1436012A2 Polymer conjugates of opioid antagonists
07/14/2004EP1436011A2 Dendrimers for use in targeted delivery
07/14/2004EP1436010A2 Water-in-oil emulsions comprising vinyl polymers carrying ethylene oxide groups in side chains, compositions, and methods
07/14/2004EP1436009A1 Pharmaceutical formulation
07/14/2004EP1436008A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
07/14/2004EP1436007A2 Compounds for use as surfactants
07/14/2004EP1436006A2 Viral inhibition by n-docosanol
07/14/2004EP1436002A1 Use of peptide vectors to improve the immune response to antigens
07/14/2004EP1435990A1 Kahalalide compounds for use in cancer therapy
07/14/2004EP1435989A1 Ptp1b inhibitors and ligands
07/14/2004EP1435981A2 Anti-tumor activity from reptile serum
07/14/2004EP1435973A1 Coadministration of transport protein with conjugated cobalamin to deliver agents
07/14/2004EP1435971A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs)
07/14/2004EP1435965A2 Pharmaceutical compositions and methods for treating cancer
07/14/2004EP1435963A2 Reduced toxicity cisplatin formulations and methods for using the same
07/14/2004EP1435945A1 Transdermal migraine therapy
07/14/2004EP1435937A2 Composition comprising paracetamol and a bitterness masking component
07/14/2004EP1435931A2 Dosage form for treatment of diabetes mellitus
07/14/2004EP1435929A1 Composition comprising cysteamine for improving lactation in dairy animals
07/14/2004EP1435925A2 Gap junctions and edhf
07/14/2004EP1435921A1 Use of a multi-layer controlled-release tablet comprising ropinirole for the manufacture of medicament for the treatment of fibromyalgia
07/14/2004EP1435918A1 Highly compressible ethylcellulose for tableting
07/14/2004EP1435917A1 Solid pharmaceutical formulation for a piperazine urea derivative
07/14/2004EP1435916A1 Powder processing with pressurized gaseous fluids
07/14/2004EP1435915A1 Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
07/14/2004EP1435914A1 Stable galenic freeze-dried pharmaceutical preparation of recombined carbohydrate-binding polypeptides
07/14/2004EP1435910A1 Novel cyclosporin analog microemulsion preconcentrates
07/14/2004EP1435909A1 Stable composition comprising particles in a frozen aqueous matrix
07/14/2004EP1435908A1 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof
07/14/2004EP1435907A2 Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
07/14/2004EP1435874A1 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
07/14/2004EP1435826A2 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
07/14/2004EP1435801A1 Encapsulated materials
07/14/2004EP1435781A1 Solvent system
07/14/2004EP1345979B1 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters
07/14/2004EP1248630B1 Use of a dermatological composition containing oligosaccharides for the treatment of skin diseases
07/14/2004EP1210350B1 Water soluble sdz-rad esters
07/14/2004EP1202996B9 Titanium derived compounds, preparation and use thereof
07/14/2004EP1171105B1 Transdermal therapeutic system with a highly effective neuroleptic agent
07/14/2004EP1169026B1 Use of ap-1 activators to treat glaucoma and ocular hypertension
07/14/2004EP1123104B1 Inherently antimicrobial quaternary amine hydrogel wound dressings
07/14/2004EP1082133B1 Stable pharmaceutical formulations for igf/igfbp
07/14/2004EP1045692B1 Skin protection composition
07/14/2004EP0984774B1 Gastroretentive controlled release microspheres for improved drug delivery
07/14/2004EP0948358B1 Stable liquid interferon formulations
07/14/2004EP0818989B1 Novel compositions of lipids and stabilizing materials
07/14/2004EP0788348B1 Container with multi-phase composition for use in diagnostic and therapeutic applications
07/14/2004CN1512982A Novel polyamine analogues as therapeutic and diagnostic agents
07/14/2004CN1512892A Orally administering parathyroid hormone and calcitonin
07/14/2004CN1512890A HCG formulation
07/14/2004CN1512884A 阿立哌唑口服溶液 Aripiprazole Oral Solution
07/14/2004CN1512882A Reconstitutable parenteral composition containing COX-2 inhibitor
07/14/2004CN1512877A Method for encapsulating active substance
07/14/2004CN1512876A Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
07/14/2004CN1512875A Inhalation capsules
07/14/2004CN1511861A Polyglycol fatty acid derivative and its medicinal combination